The effect of oral diabetes medications on glycated haemoglobin (HbA1c) in Asians in primary care: a retrospective cohort real-world data study

Table 5 Change in HbA1c values (with HbA1c denoted in mmol/mol) after gliclazide titration

Gliclazide dose after titration
0	30	40	60	80	90	120	160	240	320
	-10(-13, -8)#m=57	-12(-14, -10)#m=89		-12(-14, -11)#m=174
8(4, 10)#m=44			-2(-4, 0)#m=73
13(10, 15)#m=108				-6(-7, -3)#m=109
	4(2, 6)#m=49				-3(-7, 1)#m=38	-1(-6, 3)#m=33
11(9, 13)#m=91		3(2, 4)#m=171					-3(-4, -2)#m=233
								-3(-6, -1)#m=34
				3(2, 4)#m=172		-1(-4, 1)#m=59		-3(-6, -1)#m=113	-4(-7, -2)#m=112
							1(-2, 3)#m=50		-2(-4, 1)#m=77
							2(1, 4)#m=119	3(-2, 8)#m=31

Change in HbA1c values after gliclazide initiation, titration, or discontinuation. The values above the diagonal represent the instances where the medication has been initiated or up-titrated, while the values below the diagonal represent instances where the medication has been down-titrated or discontinued. The values refer to the mean difference in HbA1c (MD) and 95% confidence intervals. MD below 0 indicate a lowering in HbA1c while those above 0 indicate an increase in HbA1c. #m refers to the number of HbA1c pairs for that dose titration

ISSN: 1741-7015